A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes

References

• Cashman JR. (2008). Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol 4:1507–21.
   PubMed Web of Science ®Google Scholar
• Fiorentini F, Geier M, Binda C, et al. (2016). Biocatalytic characterization of human FMO5: unearthing Baeyer-Villiger reactions in humans. ACS Chem Biol 11:1039–48.
   PubMed Web of Science ®Google Scholar
• Fiorentini F, Romero E, Fraaije MW, et al. (2017). Baeyer-Villiger monooxygenase FMO5 as entry point in drug metabolism. ACS Chem Biol 12:2379–87.
   PubMed Web of Science ®Google Scholar
• Fukami T, Iida A, Konishi K, Nakajima M. (2016). Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. Biochem Pharmacol 116:153–61.
   PubMed Web of Science ®Google Scholar
• Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR. (1984). Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327–37.
   PubMed Web of Science ®Google Scholar
• Heaton A, Eiffe E, Pottabathini N, Gunning P. (2016). Functionalised and substituted indoles as anti-cancer agents. PCT Int Appl WO 2016009011.
   Google Scholar
• Holm NB, Noble C, Linnet K. (2016). JWH-018 ω-OH, a shared hydroxy metabolite of the two synthetic cannabinoids JWH-018 and AM-2201, undergoes oxidation by alcohol dehydrogenase and aldehyde dehydrogenase enzymes in vitro forming the carboxylic acid metabolite. Toxicol Lett 259:35–43.
   PubMed Web of Science ®Google Scholar
• Lai WG, Farah N, Moniz GA, Wong YN. (2011). A Baeyer-Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. Drug Metab Dispos 39:61–70.
   PubMed Web of Science ®Google Scholar
• Lee CA, Neul D, Clouser-Roche A, et al. (2010). Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347–56.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nemoto E, Hasegawa T, et al. (2011). In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734–9.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Hasegawa T, Koyanagi J, et al. (2015). Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet 40:127–135.
   PubMed Web of Science ®Google Scholar
• Meng J, Zhong D, Li L, et al. (2015). Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos 43:646–59.
   PubMed Web of Science ®Google Scholar
• Nobilis M, Mikušek J, Szotáková B, et al. (2013). Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites. J Pharm Biomed Anal 80:164–72.
   PubMed Web of Science ®Google Scholar
• Obach RS. (2004). Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89–97.
   PubMed Web of Science ®Google Scholar
• Oda S, Fukami T, Yokoi T, Nakajima M. (2015). A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51.
   PubMed Web of Science ®Google Scholar
• Ohmi N, Yoshida H, Endo H, et al. (2003). S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. Xenobiotica 33:1221–31.
   PubMed Web of Science ®Google Scholar
• Overby LH, Carver GC, Philpot RM. (1997). Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29–45.
   PubMed Web of Science ®Google Scholar
• Pataki J, Raddo PD, Harvey RG. (1989). An efficient synthesis of the highly tumorigenic anti-diol epoxide derivative of benzo[c]phenanthrene. J Org Chem 54:840–4.
   Web of Science ®Google Scholar
• Phillips IR, Shephard EA. (2017). Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13:167–81.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, de Gonzalo G, Torres Pazmiño DE, et al. (2009). Baeyer–Villiger monooxygenase-catalyzed kinetic resolution of racemic α-alkyl benzyl ketones: enzymatic synthesis of α-alkyl benzylketones and α-alkyl benzylesters. Tetrahedron: Asymmetry 20:1168–73.
   Google Scholar
• Skarydova L, Nobilis M, Wsól V. (2013). Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43:346–54.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Hofmann U, Klein K, et al. (2009). A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017–24.
   PubMed Web of Science ®Google Scholar
• Uzu S, Kanda S, Imai K, et al. (1990). Fluorogenic reagents: 4-aminosulphonyl-7-hydrazino-2,1,3-benzoxadiazole, 4-(N,N-dimethylaminosulphonyl)-7-hydrazino-2,1,3-benzoxadiazole and 4-hydrazino-7-nitro-2,1,3-benzoxadiazole hydrazine for aldehydes and ketones. Analyst 115:1477–82.
   Web of Science ®Google Scholar
• Varfaj F, Zulkifli SN, Park HG, et al. (2014). Carbon-carbon bond cleavage in activation of the prodrug nabumetone. Drug Metab Dispos 42:828–38.
   PubMed Web of Science ®Google Scholar
• Verhoeven CH, Krebbers SF, Wagenaars GN, et al. (1998). In vitro and in vivo metabolism of the progestagen Org 30659 in several species. Drug Metab Dispos 26:1102–12.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Fukami T, Nakajima M, et al. (2009). Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab Dispos 37:1513–20.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cashman JR. (2006). Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 34:19–26.
   PubMed Web of Science ®Google Scholar